370 related articles for article (PubMed ID: 24169729)
1. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
Yamamoto N; Nishimura N; Takeuchi M; Ito T; Yokozaki H; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Nishio H; Matsuo M; Imadome K; Iijima K
Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
[TBL] [Abstract][Full Text] [Related]
2. Treatment of rare co-occurrence of Epstein-Barr virus-driven post-transplant lymphoproliferative disorder and hemophagocytic lymphohistiocytosis after allogeneic stem cell transplantation.
Weber T; Wickenhauser C; Monecke A; Gläser C; Stadler M; Desole M; Ligeti K; Behrmann C; Müller-Tidow C; Müller LP
Transpl Infect Dis; 2014 Dec; 16(6):988-92. PubMed ID: 25179757
[TBL] [Abstract][Full Text] [Related]
3. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
4. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
[TBL] [Abstract][Full Text] [Related]
5. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
6. CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.
Muramatsu H; Takahashi Y; Shimoyama Y; Doisaki S; Nishio N; Ito Y; Hama A; Shimada A; Yagasaki H; Ito M; Kojima S
Int J Hematol; 2011 Jun; 93(6):779-781. PubMed ID: 21559814
[TBL] [Abstract][Full Text] [Related]
7. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte subset at time of Epstein-Barr viremia post-allogeneic hematopoietic stem cell transplantation in children may predict development of post-transplant lymphoproliferative disease: CD8:CD20 ratio as a sensitive predictor.
Althubaiti S; Ali S; Renzi S; Krueger J; Chiang KY; Schechter T; Punnett A; Ali M
Pediatr Transplant; 2019 Dec; 23(8):e13574. PubMed ID: 31496046
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
Kuriyama T; Kawano N; Yamashita K; Ueda A
J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
[TBL] [Abstract][Full Text] [Related]
11. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges.
Kittan NA; Beier F; Kurz K; Niller HH; Egger L; Jilg W; Andreesen R; Holler E; Hildebrandt GC
Transpl Infect Dis; 2011 Oct; 13(5):524-30. PubMed ID: 21395956
[TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
Chellapandian D; Das R; Zelley K; Wiener SJ; Zhao H; Teachey DT; Nichols KE;
Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
Chen DB; Song QJ; Chen YX; Chen YH; Shen DH
Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
[TBL] [Abstract][Full Text] [Related]
15. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.
Comoli P; Basso S; Zecca M; Pagliara D; Baldanti F; Bernardo ME; Barberi W; Moretta A; Labirio M; Paulli M; Furione M; Maccario R; Locatelli F
Am J Transplant; 2007 Jun; 7(6):1648-55. PubMed ID: 17511690
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
17. Prompt diagnosis and management of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and hemophagocytosis: A dreaded complication in a post-liver transplant child.
Jha B; Mohan N; Gajendra S; Sachdev R; Goel S; Sahni T; Raina V; Soin A
Pediatr Transplant; 2015 Nov; 19(7):E177-80. PubMed ID: 26184957
[TBL] [Abstract][Full Text] [Related]
18. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
[TBL] [Abstract][Full Text] [Related]
19. Systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with hemophagocytic syndrome.
Chen G; Chen L; Qin X; Huang Z; Xie X; Li G; Xu B
Int J Clin Exp Pathol; 2014; 7(10):7110-3. PubMed ID: 25400806
[TBL] [Abstract][Full Text] [Related]
20. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.
Chen DB; Liu XY; Kong FZ; Jiang Q; Shen DH
J Clin Pathol; 2021 Nov; 74(11):697-703. PubMed ID: 34011618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]